Low Dose Naltrexone (LDN)

Low Dose Naltrexone (LDN)

Low-dose naltrexone is a novel treatment for a variety of chronic pain conditions and inflammation within the central nervous system. Naltrexone is a known opioid receptor antagonist that, when prescribed in lower doses, has anti inflammatory, immunomodulatory, and analgesic properties. Low-dose naltrexone (LDN) has been recommended by physicians as a treatment for inflammatory, autoimmune, and neurological disorders. Researchers have reported that LDN regulates the immune system and minimizes pain by boosting the body’s production of endorphins. Expert physicians have found LDN to be successful in targeting pain for a wide range of illnesses including CIRS, mold/biotoxin illnesses, mast cell activation syndrome (MCAS), Lyme disease, fibromyalgia, multiple sclerosis (MS), Crohn’s Disease, and many other autoimmune or pain-related conditions that benefit from the increased levels of endorphins. Research on LDN is continuously evolving with new conditions and treatment methods being added regularly.

This list represents just a few of many listed conditions that have been treated with LDN:

• Systemic Lupus
• Alzheimer’s disease
• Arthritis
• Cancer
• Parkinson’s disease
• Hashimoto’s Disease
• Crohn’s Disease
• Psoriasis/ Eczema
• And more based on your prescriber’s diagnosis

Please contact our clinical department today at (805) 427-9053 and ask to speak with one of our expert chronic inflammatory response syndrome (CIRS), mold/biotoxin illness, MCAS, sinus, and Lyme Disease clinical pharmacists about LDN Therapy

Relevant Research

Younger, J., Parkitny, L. & McLain, D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 33, 451–459 (2014). https://doi.org/10.1007/s10067-014-2517-2 

LDN Patient Guide: https://makerx.com/wp-content/uploads/2020/06/LDN-Patient-Guide-2020-USA.pdf

Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical rheumatology, 33(4), 451–459. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain | SpringerLink

 Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses. 2009;72:333-337. doi:10.1016/j.mehy.2008.06.048.

Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013 Feb;65(2):529-38. doi: 10.1002/art.37734. 

Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical rheumatology, 33(4), 451–459. https://doi.org/10.1007/s10067-014-2517-2 

Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical rheumatology, 33(4), 451–459. https://doi.org/10.1007/s10067-014-2517-2 ; Jarred Younger, PhD, Sean Mackey, MD, PhD, Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study, Pain Medicine, Volume 10, Issue 4, May 2009, Pages 663–672, https://doi.org/10.1111/j.1526-4637.2009.00613.x 

Pilot trial of low‐dose naltrexone and quality of life in multiple sclerosis. Aug 2010. https://onlinelibrary.wiley.com/doi/abs/10.1002/ana.22006

Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol. 2018 Aug;61:178-184. doi: 10.1016/j.intimp.2018.05.020. Epub 2018 Jun 7. PMID: 29885638.

Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol. 2007 Apr;102(4):820-8. doi: 10.1111/j.1572-0241.2007.01045.x. Epub 2007 Jan 11. PMID: 17222320.